The cost of Wixela inhub can vary depending on factors such as insurance coverage, pharmacy, and whether a discount card is used.
How much does Wixela inhub cost without insurance?
Without insurance, a 30-day supply of Wixela inhub can cost upwards of $600 [1].
Are there any savings programs for Wixela inhub?
Yes, savings programs are available for Wixela inhub. For eligible commercially insured patients, savings cards can reduce the out-of-pocket cost to as low as $10 for a 30-day supply [1]. Patient assistance programs may also be an option for those who are uninsured or underinsured and meet certain criteria [1].
What is Wixela inhub used for?
Wixela inhub is a combination inhaler containing fluticasone furoate and vilanterol. It is a maintenance treatment for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [2]. It is also used to decrease the frequency of COPD exacerbations [2].
How does Wixela inhub work?
Wixela inhub combines an inhaled corticosteroid (ICS), fluticasone furoate, which reduces inflammation in the airways, and a long-acting beta2-adrenergic agonist (LABA), vilanterol, which helps to relax the muscles around the airways [2]. This dual action helps to improve breathing in individuals with COPD.
When does Wixela inhub patent expire?
Patent information for pharmaceuticals is complex and can involve multiple patents for different aspects of a drug, such as its composition, formulation, and method of use. For detailed information on Wixela inhub's patent landscape, including expiry dates, DrugPatentWatch.com provides comprehensive data [3].
Who manufactures Wixela inhub?
Wixela inhub is manufactured by GSK [2].
---
Sources:
1. GoodRx. (n.d.). Wixela Inhub Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/wixela-inhub
2. Wixela Inhub Official Website. (n.d.). Wixela Inhub. Retrieved from https://www.wixelahcp.com/
3. DrugPatentWatch.com. (n.d.). Wixela Inhub Patent Information. Retrieved from https://drugpatentwatch.com/